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SUMMARY
We evaluated the mechanism by which neutralizing
human monoclonal antibodies inhibit chikungunya
virus (CHIKV) infection. Potently neutralizing anti-
bodies (NAbs) blocked infection at multiple steps of
the virus life cycle, including entry and release.
Cryo-electron microscopy structures of Fab frag-
ments of two human NAbs and chikungunya virus-
like particles showed a binding footprint that
spanned independent domains on neighboring E2
subunits within one viral spike, suggesting a mecha-
nism for inhibiting low-pH-dependent membrane
fusion. Detailed epitope mapping identified amino
acid E2-W64 as a critical interaction residue. An
escape mutation (E2-W64G) at this residue rendered
CHIKV attenuated in mice. Consistent with these
data, CHIKV-E2-W64G failed to emerge in vivo under
the selection pressure of one of the NAbs, IM-
CKV063. As our study suggests that antibodies
engaging the residue E2-W64 can potently inhibit
CHIKV at multiple stages of infection, antibody-
based therapies or immunogens that target this re-
gion might have protective value.
INTRODUCTION
Chikungunya virus (CHIKV) is an enveloped positive stranded
RNA virus and belongs to the Alphavirus genus of the Togaviri-
dae family. The viral structural proteins, capsid (C) and three en-
velope (E) glycoproteins (E1, E2, and E3), are produced from the
subgenomic RNA as a polyprotein that is subsequently proteo-
lytically processed. Alphavirus virions have T = 4 quasi-icosahe-
dral symmetry with 240 copies of the E1-E2 heterodimer, assem-
bled into 80 spikes on the viral surface, and 240 copies of C form
an icosahedral nucleocapsid core enclosing viral genomic RNA
within the lipid membrane (Cheng et al., 1995). E2 is composed
of three domains (Voss et al., 2010): domain A is located in the
center of the spike surface and possesses the putative receptor
binding site (Smith et al., 1995); domains B and C are located at
the distal andmembrane proximal end of E2, respectively. E1 is a
type II membrane fusion protein and sits at the base of the
trimeric spike with E2 positioned on top of E1. The ectodomain
of E1 consists of three domains (Lescar et al., 2001). Domain I
links distal domain II andmembrane proximal domain III. A fusion
loop is located at the distal end of E1 domain II and is protected
by domain B of E2 (Lescar et al., 2001; Voss et al., 2010).
Alphaviruses enter cells via receptor-mediated endocytosis
(Bernard et al., 2010) and are trafficked to acidified endosomes
where the low pH environment triggers conformational rear-
rangements in the envelope glycoproteins. E2 domain B dissoci-
ates from the tip of E1 domain II, which exposes the fusion loop
(Li et al., 2010). E1 then forms a homotrimer, further exposing the
fusion loops of each monomer at the end of the trimeric complex
for insertion into host membrane (Gibbons et al., 2004).
Compared to the well-resolved entry steps of the alphavirus
life cycle, assembly and budding are less clear. The capsid
and envelope glycoproteins are required for virus particle as-
sembly and release from the surface of infected cells (Forsell
et al., 2000; Garoff et al., 2004; Soonsawad et al., 2010). How-
ever, it is unclear how formation of two icosahedral layers (capsid
and envelope glycoproteins) is coordinated andwhat viral and/or
cellular factors promote virus budding.
CHIKV is transmitted to humans byAedes speciesmosquitoes
and causes an acute febrile illness often accompanied by severe
arthralgia, with relapses for weeks to months (Couderc and Le-
cuit, 2015). In the past decade, CHIKV has spread from endemic
areas of Africa and Asia to new parts of the world. CHIKV is now
the most common alphavirus infecting humans—with millions
of individuals infected during the 2000s, including several
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incursions into Europe (Schuffenecker et al., 2006; Watson,
2007). In the winter of 2013, autochthonous cases in the Ameri-
cas were documented (Fischer et al., 2014), with the virus rapidly
spreading throughout the Caribbean islands (Lanciotti and Vala-
dere, 2014). The virus has now been disseminated to more than
40 countries in the Americas (Dı´az-Quin˜onez et al., 2015) and
likely will pose a continued threat to global human health and
economy.
There are currently no approved vaccines or treatments for
CHIKV infection. Several studies have demonstrated an essential
role of antibodies in the control of CHIKV infection (Kam et al.,
2012a, 2012b, 2012c; Lumet al., 2013).We, and others, have iso-
lated CHIKV neutralizing antibodies (NAbs) and demonstrated
their ability to protect mice and non-human primates against
CHIKV infection (Fong et al., 2014; Fric et al., 2013; Goh et al.,
2013; Hawman et al., 2013; Pal et al., 2013; Selvarajah et al.,
2013; Smith et al., 2015). In most studies, monoclonal antibodies
(mAbs) have been evaluated for their ability to block virus entry
in vitro. In our current study, we demonstrate a dual block by
CHIKV NAbs on both virus entry and release. Single-particle cry-
oelectron microscopy (cryo-EM) analysis demonstrated bridging
of two neighboring E2 molecules by Fab fragments and revealed
a common contact residue (E2-W64), which was confirmed by
neutralization escape mutant selection. Overall, our functional
and structural analyses explain the potent neutralizing activity
and strong protection profile in vivo of single NAb against CHIKV.
RESULTS
Two Potent Neutralizing Anti-CHIKV Antibodies Inhibit
Membrane Fusion
We previously reported two neutralizing monoclonal antibodies
(NAbs), C9 and the ultra-potent IM-CKV063, from individuals
who were infected and recovered from CHIKV during the 2006
outbreak in La Re´union, France (Fong et al., 2014) and a 2007
outbreak in northern Italy (Selvarajah et al., 2013). Antibodies
can block enveloped virus entry at one or more stages including
attachment, entry, and/or membrane fusion (Zinkernagel et al.,
2001). To understand how C9 and IM-CKV063 inhibit CHIKV
infection in cells, we performed pre- and post-attachment
neutralization assays. CHIKV envelope (env) glycoprotein pseu-
dotypedHIV luciferase reporter viruses were incubatedwith seri-
ally diluted C9 or IM-CKV063 before or after addition to Vero cells
at 4C. Infection was initiated by incubation at 37C and was
quantified by luciferase activity in cell lysates at 48 hr post-infec-
tion. C9 and IM-CKV063 efficiently inhibited infection when incu-
bated with virus before or after attachment to the cell surface
(Figure 1A), suggesting that both C9 and IM-CKV063 can block
CHIKV entry after virus engages receptor at the cell surface. Al-
phavirus-mediated membrane fusion is a low-pH-dependent
process that occurs in endosomes after internalization. Tomimic
virus-endosome membrane fusion at the plasma membrane, we
set up an acid-bypass viral fusion from without (FFWO) assay.
Membrane fusion was induced at the plasma membrane by
treating Vero cells pre-bound with CHIKV env pseudotyped
HIV reporter viruses with low pH buffer for 2 min. Subsequently,
cells were cultured in medium containing 20 mM NH4Cl to pre-
vent further rounds of infection via the endosomal pathway.
The optimal pH to induce membrane fusion for CHIKV env was
first determined as pH 5.5 (Figure S1) consistent with previous
reports (Pal et al., 2013). We next tested whether C9 and IM-
CKV063 blocked CHIKV-mediated membrane fusion by incu-
bating CHIKV env pseudotyped HIV reporter viruses pre-bound
to the cell surface, with serially diluted C9 and IM-CKV063 at 4C
before membrane fusion induction in the FFWO assay. Both C9
and IM-CKV063 inhibit CHIKV env-mediated membrane fusion
potently (Figure 1A). Taken together, these results suggest C9
and IM-CKV063 neutralize CHIKV entry at the low-pH-depen-
dent membrane fusion step.
Neutralizing Antibodies Block CHIKV Release
To study neutralization by C9 and IM-CKV063 with replication-
competent CHIKV, we generated a secretory Gaussia luciferase
(GLuc) expressing reporter virus (CHIKV-GLuc). We observed
similar pre-attachment, post-attachment, and FFWO neutral-
izing results for C9 and IM-CKV063 using CHIKV-GLuc as using
CHIKV env pseudotyped HIV reporter virus (Figures S2A–S2C).
Consistent with these data, C9 and IM-CKV063 failed to block
CHIKV binding to the cell surface (Figure S2D). We next
compared the neutralizing efficiency of C9 and IM-CKV063
when the mAbs were left in the culture (to allow for effects on
multiple stages in the viral life cycle) or washed out (to allow
mAb inhibition at a defined step). C9 and IM-CKV063 neutralized
CHIKV-GLuc replication more efficiently when left in the culture
medium rather thanwhenwashed out immediately after virus en-
try (Figure 1B). This pattern was recapitulated with other human
and mouse NAbs tested (Figure S3), with 10-fold lower EC50
values when the antibody was left in. These results suggested
that NAbs might inhibit additional step(s) beyond entry in virus
replication cycle. We next tested whether CHIKV release was in-
hibited by adding NAbs to the culture after infecting cells with
CHIKV-GLuc for 3 hr at 37C and extensively washing away re-
sidual virus. Viral replication and release was allowed to continue
for 20 hr in presence of 20 mM NH4Cl to prevent multiple rounds
of infection. Virus release was quantified by measuring viral RNA
levels in the supernatant by qRT-PCR or by determining levels of
infectious virus in the supernatant by inoculating fresh cells after
a 3,000-fold dilution (to decrease the concentration of NH4Cl and
antibody to non-inhibitory levels). C9 and IM-CKV063 potently
inhibited CHIKV-GLuc release in a concentration-dependent
manner, as quantified by both vRNA and virus infectivity assays
(Figure 1C). In contrast, the control mAb IM-CKV066 did not
inhibit virus release or entry. Other human and mouse NAbs
also inhibited CHIKV-GLuc release with varying efficiencies (Fig-
ures S4A and S4B). GLuc reporter gene expression positively
correlates with intracellular viral RNA level (Figure S4D). Thus,
GLuc released in the culture supernatant indicates basal viral
infection and replication. Addition of NAbs post-infection did
not affect reporter gene expression (Figure S4C), suggesting
mAbs do not inhibit post-entry and pre-viral release steps of viral
replication. C9 and IM-CKV063 also inhibited virus release from
cells infected with wild-type CHIKV East/Central/South African
genotype (ECSA) strain S27 and strain LR2006OPY1 (Figure S5).
To better understand the two anti-viral mechanisms of NAbs,
we compared abilities of mAbs versus Fab fragments of C9
and IM-CKV063 to block CHIKV entry and release (Figure 1D).
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In contrast to efficient inhibition of virus entry and release by C9
and IM-CKV063, Fab fragments of these two NAbs could only
inhibit CHIKV entry but not release, suggesting bivalent binding
is critical for NAbs to block CHIKV virus release but not entry.
C9 and IM-CKV063 Share an Epitope Centered on
Residue E2-W64
We previously used comprehensive alanine-scanning epitope
mapping to identify E2-E24, G55, W64, K66, R80, and I121 as
critical residues for binding by IM-CKV063 (Fong et al., 2014)
and E2-A162 for C9 binding (Selvarajah et al., 2013). To identify
residues that are relevant functionally for C9 and IM-CKV063
interaction with infectious virus, we generated NAb escape mu-
tants in Vero cell culture by passaging CHIKV 37997 strain under
selection of C9 or IM-CKV063. Selected escape mutant viruses
were first confirmed as resistant to selecting NAb and then
sequenced. E2-G95E and E2-W64G were identified as single
mutations in C9 and IM-CKV063 escapemutant viruses, respec-
tively. In addition to in vitro escape selection, we also performed
in vivo escape selection. IFNAR1/ mice were infected with
ten plaque-forming units (PFUs) of CHIKV 37997 strain subcu-





Figure 1. Mechanism of Potent Neutraliza-
tion by CHIKV mAb C9 and IM-CKV063
(A) Pre-and post-attachment neutralization and
FFWO neutralization assays of C9 and IM-CKV063
(see also Figure S2). CHIKV Env pseudotyped
HIV reporter viruses were incubated with serially
diluted mAbs before binding to Vero cells (Pre-
attachment) or were bound to Vero cells before
incubation with serially diluted mAbs (Post-
attachment). After washing, cells were incubated
for 48 hr before lysis for luciferase activity detec-
tion. FFWO: Vero cells were sequentially incu-
bated with CHIKV Env pseudotyped HIV reporter
viruses and serially diluted mAbs at 4C. Viral
membrane fusion was induced by incubation with
low pH buffer for 2 min. After pH normalization,
cells were cultured for 48 hr in the presence of
NH4Cl to prevent infection. Luciferase RLUs for
no-antibody controls in pre-attachment, post-
attachment, and FFWO were 38948, 27628, and
34249, respectively, and were set to 100%.
(B) Neutralization of replication-competent Gaus-
sia luciferase reporter virus (CHIKV-Gluc) by C9
and IM-CKV063 (see also Figure S3 for additional
mAbs). CHIKV-Gluc was incubated with serially
diluted mAbs for 1 hr before infecting RD cells
(MOI 0.01) for 1 hr. Left: virus-mAbs inoculum was
washed out. Right: virus-mAb inoculum was kept
in the well. Cells were cultured for 24 hr before
GLuc detection in the culture supernatant. The
non-neutralizing human mAb IM-CKV066 served
as a control. No-antibody control was set to 100%.
(C) RD cells were infected with CHIKV-GLuc for
3 hr. After extensive washing, serially dilutedmAbs
in medium containing NH4Cl were added to pre-
vent further rounds of infection. Virus release at
24 hr post-infection was measured by qRT-PCR
analysis of viral genomic RNA in culture superna-
tant (left) or by infectivity assay of the supernatant
(right). Virus release (vRNA or infectivity) was
normalized to the basal infection level that was
measured by GLuc activity in the culture super-
natant. No-antibody control was set to 100%. (See
also Figures S4 and S5.)
(D) Entry neutralization (left) and budding inhibition
(right) of CHIKV-GLuc by mAb and Fab of C9 and
IM-CKV063. As described in (B) and (C), C9 and
IM-CKV063 mAbs and their Fab fragments were
compared for their abilities to neutralize CHIKV
entry and inhibit virus release quantified by qRT-
PCR of vRNA. Data shown are representative of
three experiments performed in triplicatewith error
bars representing SD.
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post-infection. Brain tissue was collected when mice were mori-
bund at 2 or 3 days post-infection and viral RNAwas sequenced.
Mutant viruses were detected in C9-treated mice with either an
E2-G95E or E2-G95R substitution, whereas mutant viruses
with a single E2-W64R mutation emerged in animals treated
with IM-CKV063.
Toestablish that thesesinglemutations conferred resistance to
NAbs, they were introduced into CHIKV-GLuc reporter virus and
tested for antibody inhibition of virus entry (Figure 2A) or release
(Figure 2B). Consistent with sequencing results, E2-G95E and
E2-G95R mutant viruses were resistant to C9-mediated entry
and release inhibition. The E2-W64G mutation conferred CHIKV
resistance to both IM-CKV063-mediated entry and release inhibi-
tion, whereas E2-W64Rwas onlyweakly resistant to IM-CKV063.
Of note, while a change at G95 rendered CHIKV resistant specif-
ically to C9, the W64G mutation conferred resistance to both C9
and IM-CKV063. Similar results were observed when the muta-
tions were engineered into CHIKV LR2006-OPY1 stain, with
bothescapeviruses remainingsensitive toCHK-152,whichbinds
to an adjacent residue, E2-D59 (Pal et al., 2013; Sun et al., 2013)
(Figure S6). These results suggest that residue E2-W64 in E2
comprises part of a common epitope shared by C9 and IM-
CKV063, whereas E2-G95 is specific for C9.
To define the location of the residues that potentially boundC9
and IM-CKV063, E2-W64 and E2-G95 were mapped onto the
CHIKV E1-E2 atomic structure (Voss et al., 2010) (Figure 2C).
Both E2-W64 and E2-G95 are solvent accessible and located




Figure 2. Mapping and Characterization of C9 and IM-CKV063 Escape Mutants
(A) CHIKV-GLuc reporter viruses carrying indicated single escape mutations are resistant to antibody-mediated neutralization of entry (see also Figures S6).
Similar to Figure 1B, WT and mutants GLuc reporter viruses were incubated with serially diluted mAbs before infecting RD cells at an MOI of 0.5. Infection was
presented by GLuc activity in the supernatant at 24 hpi. Virus infection was normalized to a no-antibody control. Results are representative of three independent
experiments in triplicate.
(B) CHIKV-GLuc reporter viruses encoding indicated single escape mutations are resistant to antibody-mediated inhibition of virus release (see also Figures S6).
Similar to Figure 1C, RD cells were infected with WT or mutant GLuc reporter viruses for 3 hr before incubated with MAbs serially diluted in medium containing
NH4Cl to prevent further rounds of infection. Virus release at 24 hr post-infection was measured by an infectivity assay. No-antibody treatment was set to 100%.
Data shown are representative of three experiments performed in triplicate with error bars representing SD.
(C) Mapping of C9 and IM-CKV063 escape residues on the crystal structure of the mature CHIKV envelope glycoprotein complex (PDB code 2XFB) in top view of
trimer (left), side view of trimer (middle), and E1E2 dimer (right). Pink, E2; cyan, E1.
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in one spike, which consists of three E1-E2 heterodimers. E2-
W64 is located at the apex of the E2 trimer, whereas E2-G95 is
located below E2-W64 within the cavity. Alignment of all avail-
able 422 E2 proteins from different CHIKV strains in GenBank
and 212 E2 proteins in VIPR (http://www.viprbrc.org/brc/home.
spg?decorator=vipr) demonstrated that both E2-W64 and E2-
G95 are 100% conserved.
C9 and IM-CKV063 Bind Similarly to Chikungunya
Virus-like Particles
To gain further insight as to how C9 and IM-CKV063 interact and
neutralize CHIKV, we determined single-particle cryo-electron
microscopy (cryo-EM) structures at 15.3, 14.9, and 11.2 A˚ reso-
lution for chikungunya (CHIK) virus-like particles (VLPs) (Akahata
et al., 2010; Sun et al., 2013), CHIK VLPs in complex with C9 Fab
fragment, and CHIK VLPs in complex with IM-CKV063 Fab frag-
ment, respectively (Figure 3A). Three molecules of C9 Fab or IM-
CKV063 Fab could be distinguished on top of each q3 or i3
CHIKV spike. We fitted a generic Fab crystal structure into the
difference maps after subtracting VLP density from VLP-C9
Fab and VLP-IM-CKV063 Fab density maps, using the fitting
function of UCSF Chimera. CHIK VLP pseudo-atomic resolution
coordinates also were placed into the VLP-C9 Fab and VLP-IM-
CKV063 Fab electron density maps (Figure 3B). Both C9 and
IM-CKV063 Fab fragments bound two neighboring E2 proteins
in one spike with the complementarity determining regions
(CDRs) interacting with domain A of E2 and the back of the var-
iable region appeared to lie down on an adjacent E2 (Figure 3C).
The footprints of C9 and IM-CKV063 Fab fragments on the sur-
Figure 3. C9 and IM-CKV063 Span Two
Neighboring E2 Molecules in One Spike
(A) Cryo-EM reconstruction of CHIKV (S27) virus-
like particle (VLPs) (right), VLP in complex with C9
Fab fragments (left), and VLPs in complex with IM-
CKV063 fragments (middle).
(B) Fitting of E1-E2 and Fab crystal structures into
the viral spike at the q3-fold axis of the cryo-EM
density map of C9 Fab-bound VLPs (left) and IM-
CKV063 Fab-bound VLPs (right). Blue, Fab; pink,
E2; cyan, E1.
(C) C9 Fab (left) and IM-CKV063 Fab (right) insert
between domain A of one E2 (left) and domain B of
a neighboring E2 (right) in one viral spike.
(D and E) E2-W64was labeled in black, and E2-G95
was labeled in gray. Comparison of C9 Fab (blue)
and IM-CKV063 Fab (hot pink) binding to a viral
spike in top view (D) and side view (E).
face of the CHIK VLPs were determined
with the RIVEM program (Xiao and Ross-
mann, 2007) (Figure 4). Both C9 and IM-
CKV063 Fab spanned domain A and the
b-ribbon connector of one E2 and domain
A and B of a neighboring E2 within one
spike. In this way, C9 and IM-CKV063
may hinder sterically the movement of
the B domain that is activated by acid pH
and required for membrane fusion. This
structural model is consistent with our results showing that C9
and IM-CKV063 both inhibit low (low pH-dependent) pH-depen-
dent plasma membrane fusion (see Figure 1A).
A comparison of C9 and IM-CKV063 interaction with the
CHIKV spike revealed similar binding by C9 and IM-CKV063 to
the crest of domain A on E2, but a deeper protrusion of C9 into
the cavity of the spike (Figures 3D and 3E). This is consistent
with C9 and IM-CKV063 sharing one contact residue (E2-W64)
at the top of the cavity, whereas C9 also requires another residue
(E2-G95), located at a lower position in the cavity (Figure 2C).
Importantly, the location of E2-W64 was confirmed in the foot-
prints of C9 and IM-CKV063, although E2-G95, which is situated
below E2-W64, was not visible in the projection map (Figure 4).
The cryo-EM determined footprints of C9 and IM-CKV063 also
included residues E2-A162 and E2-I121 that were identified
by alanine scanning epitope mapping for C9 and IM-CKV063,
respectively (Fong et al., 2014; Selvarajah et al., 2013).
W64G Mutation Results in an Attenuated CHIKV
Because W64R was selected in vivo as an escape mutation yet
rendered CHIKV only partially resistant to IM-CKV063 in vitro, we
tested whether this virus was fully resistant to IM-CKV063 in vivo
in a neonatal mouse model of infection (Couderc et al., 2008).
Previously, we reported that 10 mg of IM-CKV063 protected
100% of 9-day-old C57BL/6J mice against lethal CHIKV S27
(5 3 105 PFUs) infection when administrated concurrently with
virus (Fong et al., 2014). Here, we evaluated whether W64R
and W64G mutant CHIKV 37997 were resistant to IM-CKV063
protection in neonatal mice (Figure 5A). Although administration
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of 5 3 105 PFUs of either wild-type (WT) or W64R CHIKV 37997
resulted in 100% lethality in mice, the W64R mutant showed a
delayed time to death (mean survival time of 6 versus 9 days,
p < 0.01). IM-CKV063 provided similar protection against CHIKV
37997 WT and W64R (10 mg protected 30% of WT versus 20%
W64R-infected mice from lethality, p > 0.05; 30 mg protected
Figure 4. Footprints of C9 and IM-CKV063 Span Two Neighboring E2
‘‘Roadmaps’’ of the footprints of C9 (A) or IM-CKV063 (B) Fabs on the VLP surface at q3 spike. To differentiate between amino acids in three different q3-fold
related subunits, their identity is defined as the amino acid sequence number in E1 + 2,000, 3,000, and 4,000, and in E2 + 2,500, 3,500, and 4,500 individually. The
surface is colored according to radial distance from the center of the VLPs. Domain As of three E2 are bounded by black, gray, and purple lines, respectively. B
domains of E2 are bounded by white lines. The b-ribbon connectors of E2 are bounded by magenta lines. The footprints of the Fabs on the VLP surface are
outlined in yellow. The footprint of a single Fab is boxed in white, and an enlarged image of the boxed area is shown on the right. E2-W64 is labeledwith white star.
2558 Cell Reports 13, 2553–2564, December 22, 2015 ª2015 The Authors
75% of WT versus 100% W64R-infected mice, p > 0.1). Thus,
and consistent with our in vitro data (Figure 2A), the W64R
mutant remained sensitive to IM-CKV063 neutralization; even
though it emerged as a variant under IM-CKV063 selection
in IFNAR1/ mice, it did not confer significant resistance in
the WT mouse model. Somewhat unexpectedly, mice infected
with 53 105 PFUs of W64Gmutant survived for at least 3 weeks
(Figure 5A), and a 30-fold higher virus dose caused death in only
10% of mice (Figure 5B). These results indicated that the fully
resistant W64G mutant was attenuated in neonatal mice.
We next employed a non-lethal mouse model of CHIKV-
induced arthritis (Morrison et al., 2011) to compare the ability
of WT and W64G mutant CHIKV to cause joint disease in
3-week-old C57BL/6J mice. 103 PFUs of WT and W64G mutant
CHIKV 37997 were inoculated in the left rear footpad. During the
acute phase, wemeasured ankle swelling for each mouse at day
3 and 7 post-infection and observed less swelling with theW64G
mutant compared to WT virus (Figure 5C). Cytokine and chemo-
kine levels in mouse serum at day 3 and 7 post-infection also
were measured. Compared to animals infected with WT virus,
mice infected with CHIKV W64G mutant produced lower serum
levels of several cytokines and chemokines, including inter-
leukin-1b (IL-1b), IL-5, IL-13, and eotaxin (Figure 5D). In a recent
meta-analysis of anti-CHIKV patient signatures all of these cyto-
kines, as well as eotaxin, were found to be elevated in acute
infection (Teng et al., 2015). Thus, analogous to results in
neonatal mice, the W64G mutant virus was attenuated in its
ability to cause joint inflammation and swelling in juvenile
3-week-old mice.
IM-CKV063 Provides Strong Protection against
CHIKV-Induced Joint Disease In Vivo
C9 and IM-CKV063 neutralized CHIKV entry and release at com-
parable potency, but it wasmore difficult for virus to escape from
IM-CKV063 than C9 in vivo. To test whether this correlated with
their different protective activities in vivo, we compared the abil-
ity of C9 and IM-CKV063 with previously identified moderate hu-
manNAb IM-CKV065 (Fong et al., 2014) and potent mouse NAbs
(Pal et al., 2013) to protect mice from arthritis caused by CHIKV-
LR infection (Morrison et al., 2011). Human or mouse NAbs were
administered to 4-week-old-mice 4 hr after subcutaneous infec-
tionwith 103 PFUs of CHIKV in the left rear footpad. Compared to
isotype control mAb, IM-CKV063 limited the CHIKV burden in the
ipsilateral ankle to the limit of detection, prevented viral spread to
the contralateral ankle joint (Figure 6A), and showed superior ac-
tivity compared to the remainder of the panel of mouse and hu-
man NAbs. Although treatment with all tested NAbs reduced
ankle joint swelling at day 3 when compared to the isotype con-
trol mAb, IM-CKV063 therapy reduced the swelling closest to the
baseline (Figure 6B). These results demonstrated that IM-
CKV063 provides superior protection compared to other NAbs
against CHIKV-induced infection and arthritis in vivo in mice.
DISCUSSION
In the current study, we characterized the neutralizing mecha-
nisms of two previously identified potently inhibitory antibodies,
C9 (Selvarajah et al., 2013) and IM-CKV063 (Fong et al., 2014). A
comparison of neutralization efficiency between NAbs left in cul-
ture after infection and NAbs washed out after infection led us to
identify post-entry inhibition by CHIKV NAbs as a potent mech-
anism of inhibition. To escape from NAbs, mutant CHIKV ac-
quired resistance to both entry and release inhibition by NAbs,
suggesting the importance of these blocks to the CHIKV life cy-
cle. mAb-mediated inhibition of viral release has been described
for influenza virus (Dowdle et al., 1974), bovine leukemia virus
(Driscoll et al., 1977), herpes virus (Shariff et al., 1991), vaccinia
virus (Vanderplasschen et al., 1997), rubella virus (Corboba
et al., 2000), Marburg virus (MARV) (Kajihara et al., 2012), and
CHIKV (Masrinoul et al., 2014). However, most of these studies
utilized mAbs that do not independently neutralize virus entry.
Recently, inhibition of viral release was described for two
MARV glycoprotein-specific mAbs, whereby these mAbs in-
hibited MARV release by tethering budded virus particles to
the glycoproteins present on the cell surface via bivalent binding
(Kajihara et al., 2012). A recent study reported a murine mAb
(CK47) targeting E1-domain III that inhibited CHIKV release but
not entry (Masrinoul et al., 2014), although high concentration
of antibody (250 mg/ml) was required, and no in vivo studies
were performed. A non-neutralizing antibody used in our study
that targets E1-domain II (IM-CKV066) (Fong et al., 2014) failed
to block CHIKV release. As cells used for virus release assays
in our study lack Fc receptor, the inhibition of virus release by
NAbs is unlikely due to the tethering of virus by immunoglobulin
G (IgG) to cell surface. In our study, bivalent binding is critical for
NAbs to block CHIKV release but not entry. It will be interesting
to test whether NAbs inhibit CHIKV release by tethering budded
virus particles to viral glycoprotein at the cell surface or through a
different mechanism. Future studies are needed to understand
the mechanism by which mAbs targeting different epitopes on
E1 and E2 block the same release step of the CHIKV life cycle.
In our study, all neutralizing antibodies that blocked CHIKV
release also inhibited entry. The relative contribution of neutrali-
zation and viral budding inhibition, as well as other potential
mechanisms of anti-viral activity, to in vivo protection will require
further studies.
Single-particle cryo-EM structures revealed that C9 and IM-
CKV063 Fab molecules bridge adjacent individual E2 subunits
within the same spike on CHIKV VLPs. The fitting of a Fab frag-
ment into the cryo-EM density map suggests that both C9 and
IM-CKV063CDRs interact with the top rim of a cavity surrounded
by three E2molecules and tilt toward the neighboring E2with the
groove of the variable region positioned on it. This mode of bind-
ing of one Fab fragment to two neighboring E2 differs from that
reported for four mouse CHIKV NAbs (CHK-152, CHK-9,
m242, and m10) in which one Fab binds to one E2 without inter-
acting with other E2 molecules in a given spike (Sun et al., 2013).
Nonetheless, analogous cross-linking of neighboring E glyco-
proteins was reported for a human NAb against West Nile virus,
CR4354 (Kaufmann et al., 2010).
By interacting with domain A and the b-ribbon connector of
one E2 and domain A and B of a neighboring E2, C9, and IM-
CKV063 may prevent conformational changes that are required
for fusion loop exposure. This model is consistent with our re-
sults showing both C9 and IM-CKV063 blocked low pH-depen-
dent membrane fusion after virus binds to the cell. A similar
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mechanism, involving the constraint of CHIKV E2 domain A and
domain B was proposed for a potent mouse NAb CHK-152 (Sun
et al., 2013). However, for CHK-152, the CDRs interact with
domain A and domain B of a single E2 subunit in a given spike,
rather than adjacent subunits. The epitopes for CHK-152 (Pal
et al., 2013), C9, and IM-CKV063 all were mapped to E2-domain
A by escape mutant selection and confirmed by cryo-EM. Addi-
tional residues were identified by epitope mapping with alanine
Figure 5. Virulence of WT and W64 Mutants In Vivo
(A) 9-day-old C57BL/6J mice were infected with 2.6 3 105 PFUs of WT or the indicated escape mutant viruses via an intradermal route. Concurrently, animals
were administered via an intraperitoneal injection the indicated amounts of IM-CKV063.
(B) C57BL/6J mice were infected with increasing amount of CHIKV (37997) via intradermal route. The survival curves were constructed from data of at least two
independent experiments with a total of between five and 15 mice per group.
(C) Three-week-old WT C57BL/6J mice were inoculated in the left rear footpad with 103 PFUs of WT or W64G CHIKV. At days 3 and 7 after infection, ankle size
was measured and relative swelling was calculated for each mouse.
(D) At days 3 and 7 after infection, serum was collected and analyzed for the indicated cytokines and chemokines. Statistically significance was determined by
unpaired t test (*p < 0.05; **p < 0.01).
Figure 6. IM-CKV063 Provides Superior
Protection against CHIKV Compared to
Other Tested NAbs
Four-week-old WT mice were treated with 100 mg
of indicated mAbs 4 hr following subcutaneous
inoculation with 103 FFU CHIKV-LR in the left rear
footpad. WNV E60 and WNV hE16 served as
mouse and human isotype control mAbs.
(A) Viral load was determined in both ipsilateral
and contralateral ankles at 3 days post-infection.
Statistical significance was determined by a
Kruskal-Wallis test with a Dunn’s multiple com-
parison test (*p < 0.05; **p < 0.01; ***p < 0.001) (n =
6–7).
(B) Footpad size in the ipsilateral joint was
measured prior to and 3 days following infection.
Statistical significance was determined by ANOVA
with a Dunnett’s multiple comparison test (**p <
0.01; ***p < 0.001) (n = 6–7).
scanning for C9 (Selvarajah et al., 2013)
and IM-CKV063 (Fong et al., 2014), and
they are located in or close to the C9
and IM-CKV063 footprints on CHIKV.
Small differences in the epitope mapping
of the footprints between this study and
Fong et al. (2014) are likely due to map-
ping being performed using point muta-
tions in cell-surface expressed viral
glycoproteins, rather than icosahedral vi-
rus-like particles and live virus escape
mutants as performed in the current
study. Although no residue in domain B
was found critical for CHK-152, C9,
or IM-CKV063 binding based on neutral-
ization escape or other mutagenesis
studies, portions of domain B were
apparent in their cryo-EM footprints.
One mAb per E1-E2 trimer may be suffi-
cient to constrain E2 and thus hinder the
low-pH-dependent conformational changes. This mechanism
may explain the basis for their neutralizing ability, particularly
of the ultrapotent IM-CKV063.
Escapemutant selection and cryo-EM structure analyses sug-
gest that C9 and IM-CKV063 share a key residue, E2-W64, as
part of their epitopes. In a recent report describing another set
of human NAbs against CHIKV, five of 18 strong NAbs and
one of five moderate NAbs included W64 in their epitopes
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(Smith et al., 2015), suggesting E2-W64 may comprise part of
dominant neutralizing epitope of CHIKV glycoprotein. E2-W64
is conserved among all the sequenced CHIKV strains available
in GenBank and VIPR databases. Unexpectedly, W64 appears
important for CHIKV pathogenesis, with the W64G mutation
attenuating CHIKV in a neonatal mouse model of lethality and
an arthritis model in juvenile mice.
Although NAbs are being explored to treat acute or chronic
CHIKV infection, rapid emergence of resistant mutants could
render therapeutic antibodies less useful. W64G was selected
by IM-CKV063 in vitro, whereas only the less resistant mutant,
W64R, was selected in vivo. The failure of CHIKV to mutate to
the fully resistant W64Gmutant in vivomight explain the superior
protection observed from IM-CKV063 compared to other NAbs
(e.g., C9 and CHK-152) to which escape mutants readily
emerged (Pal et al., 2013). The relative attenuation of the fully
resistant W64G mutant may contribute to the potency of IM-
CKV063 to reduce inflammation induced by CHIKV infection.
Although more study is warranted, it suggests that IM-CKV063
may be a good candidate for monotherapy against CHIKV
infection.
In summary, our study demonstrated blocks in the CHIKV
replication cycle by NAbs at both the entry and release steps.
E2-W64 is a key residue targeted by multiple Nabs generated
by independent groups from different subjects, andW64Gmuta-
tion rendered CHIKV attenuated in vivo. The E2-W64 residue and
its complete epitope may have value in structure-based vaccine
design or antibody therapeutic development against CHIKV.
EXPERIMENTAL PROCEDURES
Cells, viruses, antibodies, and mice used in the study are described in the
Supplemental Information.
Neonatal Mouse Model
Animal experiments were performed with the approval of the Institutional An-
imal Care and Use Committee at PMI Preclinical LLC, San Carlos, CA (Assur-
ance Number: A3367-01). 9-day-old mice were transferred to a biosafety level
3 facility in static disposable cages (Innovive) with their mothers. Neonatal
C57BL/6J mice were infected with CHIKV intradermally in the ventral thorax.
Each mouse was injected via an intraperitoneal route with test mAb in 0.2 ml
PBS immediately prior to CHIKV infection. Mice were then observed daily for
up to 20 days. Results were analyzed using Kaplan-Meier survival curves
and GraphPad Prism software.
Arthritis Mouse Model
Animal experiments were performed with the approval of the Institutional
Animal Care and Use Committee at the Washington University School of Med-
icine (Assurance Number: A3381-01). 3-week-old C57BL/6J mice were inoc-
ulated with CHIKV subcutaneously in the left footpad with 103 PFUs of CHIKV
in PBS supplemented with 1% heat inactivated FBS. Joint swelling was moni-
tored via left and right foot measurements (width 3 height) using digital cali-
pers. Sera were collected at days 3 and 7 after infection.
NAb Protection
A single 100-mg dose of human NAbs C9, IM-CKV063, CKV065, and mouse
NAbs CHK-166, CHK-152, CHK-9, and CHK-95 was administered to 4-week-
old C57BL/6J mice 4 hr after subcutaneous infection with 103 PFUs of CHIKV
(LR2006-OPY1) in the left rear footpad. Mouse West Nile virus (WNV) mAbs
E60 and humanized hE16 were used as the isotype controls. Joint swelling
wasmonitored via left footmeasurements. Tissueswere collected at day 3 after
infection and virus was titered by focus forming assay (Pal et al., 2013) using
chimeric human CHK-9 as the detection antibody for CHIKV.
Mutagenesis of CHIKV Infectious Clone
Site-directed mutagenesis was performed by standard overlapping PCR
approach. Primers for site-directed mutagenesis were listed in Table S1.
Molecular clones of mutant viruses confirmed by sequencing.
Cryo-EM Reconstruction of CHIKV VLPs in Complex with C9 or
IM-CKV063 Fab Fragment
CHIKV VLPs production was described before (Fong et al., 2014). C9 and
CVK063 Fab fragments were generated from purified C9 and IM-CKV063
IgG using Pierce Fab preparation Kit (Thermo Fisher Scientific). The purified
C9 and IM-CKV063 Fab molecules were mixed with CHIKV VLPs at 3:1
(Fab:E2) molar ratio for at least 30 min on ice. Samples were flash-frozen on
Quantifoil copper grids (R2/1, 200 mesh) in liquid ethane with a Vitrobot




CHIK reporter viruses were incubated with serially diluted mAbs at 4C for 1 hr
before added to Vero cells for 1 hr binding at 4C. After washing three times,
cells were incubated in fresh medium for 48 hr at 37C before lysis and assay-
ing for luciferase activity.
Post-attachment
CHIK reporter viruses were bound to Vero cells at 4C for 1 hr. After washing
three times, cells were incubated in serially diluted mAbs for 1 hr at 4C. After
additional washing, cells were incubated in fresh medium for 48 hr at 37C
before lysis and assaying for luciferase activity.
FFWO
Vero cells were incubated sequentially with CHIK reporter viruses for 1 hr at
4C and serially diluted mAbs for 1 hr at 4C. Viral membrane fusion was
induced by incubation with buffer of pH 5.5 at 37C for 2 min. After pH
normalization, cells were cultured for 48 hr in the presence of 20 mM
NH4Cl to prevent infection via the endosomal pathway before lysis and as-
saying for luciferase activity. Virus infection was normalized to a no-antibody
control.
Release Inhibition Assays
RD cells were seeded in 96 well plates at 4 3 104 cells per well. Cells were in-
fected with CHIKV-GLuc at MOI 0.5 for 3 hr at 37C. After washing for three
times, serially diluted mAbs in medium containing 20 mM NH4Cl were added
to prevent further rounds of infection. At 20 hr post-infection, culture superna-
tants were harvested. GLuc activity in the supernatant represented the basal
infection levels. Virus released in the supernatant at 24 hr post-infection was
measured. (1) Viral RNA in culture supernatant was extracted by the QIAamp
Viral RNA Mini kit (QIAGEN) following the manufacturer’s protocol. Isolated
RNA was analyzed by qRT-PCR and compared to a standard curve generated
from CHIKV-GLuc plasmid. Primers are listed in Table S2. (2) Viral infectivity in
the supernatant was measured by infecting fresh RD cells after a 3,000-fold
dilution. GLuc activities at day 2 after infection were measured. Virus release
efficiency was calculated by dividing either vRNA genome copy number or
virus infectivity in the supernatant by basal infection level. Virus release effi-
ciency without antibody treatment was set to 100%.
Escape Mutant Selection
In Vitro Selection
23 105 PFUs of CHIKV-37997 were incubated with 10 mg/ml of C9 and 13 106
PFUs of CHIKV-37997 were incubated with 5 mg/ml of IM-CKV063 for 1 hr at
37C. Virus-NAb mixtures were added to Vero cells in 96-well-plate for 24 hr
of infection. At each passage, half of the supernatant was mixed with 20 mg/
ml of C9 or 10 mg/ml of IM-CKV063 for 1 hr at 37C. The mixtures were added
to fresh Vero cells to infect 2 hr. After three passages for C9 resistant virus
selection and five passages for IM-CKV063 resistant virus selection, escape
mutant viruses were selected. Viral RNA was extracted from the supernatant
using a QIAamp Viral RNA Mini kit (QIAGEN) and reverse transcribed into
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cDNA with random hexamer primer using the Superscript III Reverse Tran-
scriptase kit (Invitrogen). CHIKV structural gene was amplified by PCR and
sequenced.
In Vivo Selection
IFNAR1/mice were infected with ten PFUs of CHIKV 37997 strain subcuta-
neously and received 100 mg/mouse C9 or 50 mg/mouse IM-CKV063 at 24 hr
post-infection. Brain tissue was collected when mice were moribund at 2 or
3 days post-infection, and viral RNA was extracted from the tissue using
RNeasy Mini kit (QIAGEN). cDNA was synthesized using the Superscript III
Reverse Transcriptase kit (Invitrogen), and CHIKV structure gene was ampli-
fied by PCR and sequenced.
Mouse Cytokine and Chemokine Assay
23mouse cytokines and chemokines in serumwere measured by the Bio-Plex
Pro Mouse Cytokine 23-Plex Immunoassay (Bio-Rad) according to the manu-
facturer’s instruction.
Statistical Analyses
All data were analyzed using Prism software and statistical significance was
assigned when p values were <0.05. EC50 values were determined using
non-linear regression. Cytokine and chemokine levels were analyzed using
the unpaired t test. Viral titers were analyzed using the Kruskal Wallis test
with a Dunn multiple comparisons test. Joint swelling was analyzed using a
one-way ANOVA adjusting for repeated-measures with a Dunnett’s multiple
comparisons test.
ACCESSION NUMBERS
The cryo-EM density maps of CHIKV VLPs, VLPs in complex with C9
Fab, and VLPs in complex with IM-CKV063 Fab were deposited with the
EM Data Bank under accession numbers EMD: 6466, 6467, and 6457,
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